All Resources

Expert interviews discussing psychosocial support for individuals at risk of T1D 

At the BR1DGE symposium at ATTD 2025, leading experts discussed how innovation can evolve the early detection and management of T1D (type 1 diabetes). 

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.  

Using a sample pediatric case study (Rosa), this video describes how autoantibody screening can enable early detection of presymptomatic T1D, providing a window of opportunity to prepare for clinical diagnosis

Early identification of presymptomatic autoimmune T1D may reduce the psychological burden experienced at diagnosis by giving time for preparation and education

Rosa is an 8-year-old child with presymptomatic autoimmune T1D, but neither she nor her family know this yet. Without prior knowledge, she may be at increased risk of DKA at clinical onset of T1D

People positive for at least one islet autoantibody should be monitored regularly

GRS helps to select individuals at high risk for T1D for screening

Explore the association of GWAS and GRS and how they can improve T1D

T1D has three different stages, characterized by increasing loss of beta-cell function

CD8+ T cell exhaustion rate predicts progression of T1D

People identified early through screening programs have milder disease and better quality of life compared to control

The number, type, and titer of islet autoantibodies detected in T1D screening tests provide valuable information about potential progression to clinical T1D.